Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™
Status:
Completed
Trial end date:
2016-08-20
Target enrollment:
Participant gender:
Summary
This is a Phase 4, interventional, multicenter study of subcutaneous Rebif® (interferon
beta-1a) using RebiSmart™ device to assess effectiveness and adherence of treatment in
subjects with clinically isolated syndrome (CIS) or relapsing multiple sclerosis (RMS).
Phase:
Phase 4
Details
Lead Sponsor:
Merck KGaA Merck KGaA, Darmstadt, Germany
Collaborator:
Merck Romania SRL, an affiliate of Merck KGaA, Darmstadt, Germany